KBC Group NV Purchases 902 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

KBC Group NV lifted its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 38.8% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,225 shares of the company’s stock after purchasing an additional 902 shares during the period. KBC Group NV’s holdings in 10x Genomics were worth $73,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in 10x Genomics by 1.0% in the first quarter. Vanguard Group Inc. now owns 9,101,536 shares of the company’s stock worth $341,581,000 after acquiring an additional 90,204 shares during the period. Covestor Ltd raised its holdings in 10x Genomics by 501.7% in the 1st quarter. Covestor Ltd now owns 1,047 shares of the company’s stock worth $39,000 after purchasing an additional 873 shares during the period. Axxcess Wealth Management LLC purchased a new position in 10x Genomics during the first quarter valued at $237,000. Advisors Asset Management Inc. grew its holdings in 10x Genomics by 27.3% during the first quarter. Advisors Asset Management Inc. now owns 25,228 shares of the company’s stock valued at $947,000 after purchasing an additional 5,406 shares during the period. Finally, Lazard Asset Management LLC grew its holdings in 10x Genomics by 23.1% during the first quarter. Lazard Asset Management LLC now owns 74,540 shares of the company’s stock valued at $2,797,000 after purchasing an additional 13,972 shares during the period. Hedge funds and other institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Performance

Shares of TXG opened at $14.31 on Friday. The stock has a market capitalization of $1.73 billion, a PE ratio of -9.35 and a beta of 1.87. The company’s fifty day moving average is $17.57 and its 200 day moving average is $19.97. 10x Genomics, Inc. has a fifty-two week low of $12.95 and a fifty-two week high of $57.90.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. The business had revenue of $151.65 million during the quarter, compared to analysts’ expectations of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The business’s revenue was down 1.3% on a year-over-year basis. During the same period last year, the company posted ($0.51) EPS. As a group, research analysts forecast that 10x Genomics, Inc. will post -1.4 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on TXG. Morgan Stanley lowered their price objective on 10x Genomics from $50.00 to $46.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. JPMorgan Chase & Co. dropped their price target on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, October 30th. Leerink Partnrs upgraded shares of 10x Genomics to a “strong-buy” rating in a research note on Tuesday, September 3rd. Leerink Partners assumed coverage on 10x Genomics in a research note on Tuesday, September 3rd. They issued an “outperform” rating and a $35.00 price target for the company. Finally, Citigroup decreased their price target on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, 10x Genomics currently has an average rating of “Moderate Buy” and an average target price of $29.19.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.